| The ACE2 antibody targets Angiotensin-converting enzyme 2, a type I membrane glycoprotein encoded by the ACE2 gene. Angiotensin-converting enzyme 2 functions as a carboxypeptidase that cleaves angiotensin II to angiotensin (1-7), a peptide with vasodilatory and anti-inflammatory effects. By opposing the classical renin-angiotensin system, Angiotensin-converting enzyme 2 maintains cardiovascular, renal, and pulmonary homeostasis. The ACE2 antibody provides a critical reagent for studying blood-pressure regulation, viral entry mechanisms, and tissue-specific expression of this pivotal enzyme.Angiotensin-converting enzyme 2 is expressed in the vascular endothelium, lungs, heart, kidneys, and intestinal epithelium. Its catalytic domain hydrolyzes angiotensin II to produce angiotensin (1-7), which signals through the Mas receptor to counteract vasoconstriction and fibrosis. The ACE2 antibody enables precise detection of this enzyme in tissues, helping define its role in vascular tone and inflammatory control. Loss or downregulation of ACE2 disrupts this protective axis, predisposing tissues to hypertension, oxidative stress, and organ injury.In addition to its enzymatic role, Angiotensin-converting enzyme 2 serves as a functional receptor for several coronaviruses, including SARS-CoV and SARS-CoV-2. Viral spike proteins bind to the extracellular domain of ACE2 to mediate cell entry. The ACE2 antibody supports virology and pathogenesis studies by enabling analysis of receptor abundance and distribution across tissues. Mapping ACE2 expression helps clarify host susceptibility and disease severity patterns in respiratory and cardiovascular systems.Beyond infection biology, ACE2 participates in glucose metabolism, heart remodeling, and kidney filtration. Experimental models show that enhancing ACE2 activity mitigates cardiac hypertrophy and diabetic nephropathy. The ACE2 antibody supports quantification of these protective effects and is frequently used to monitor therapeutic modulation of the renin-angiotensin system. Dysregulated ACE2 expression has also been linked to inflammatory lung injury and endothelial dysfunction.The ACE2 antibody is validated for western blotting, immunohistochemistry, and immunofluorescence, producing clear membrane and cytoplasmic staining consistent with its localization. NSJ Bioreagents provides this antibody with verified specificity and reproducibility for cardiovascular, infectious-disease, and molecular-biology research. By enabling accurate detection of Angiotensin-converting enzyme 2, the ACE2 antibody supports exploration of vascular signaling, viral pathogenesis, and therapeutic strategies aimed at restoring physiological balance. |
